Novartis North American oncology operations head Deborah Dunsire will succeed Mark Levin as CEO of Millennium by Aug. 1. Levin, a Millennium co-founder, will become a member of the board. Dunsire has headed Novartis' North American oncology operations since 1997; over the last eight years, the U.S. business achieved a compounded annual growth rate of 25%. Dunsire plans to take a "fresh look" at the Millennium business and will develop a strategy aimed at helping the company meet its goal of non-GAAP profitability by 2006...
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.